/** blogpostTitle: NephroPlus Q1 FY27: Operating leverage, international mix, and disciplined expansion blogpostSlug: nephroplus-q1 blogpostCoverImageDescription: Ultra-realistic corporate scene showing a clean analytics workstation with multiple monitors displaying a line chart of quarterly revenue growth, a bar chart of EBITDA and PAT trends, and a pie chart showing a 55 percent India and 45 percent international revenue mix; in the background, a softly blurred modern dialysis clinic corridor with empty chairs and equipment silhouettes to indicate healthcare services scale; neutral lighting, professional financial aesthetic, no logos or text labels. blogpostShortTitle: NephroPlus Q1 FY27 growth and margins */

NephroPlus Q1 FY27: Operating leverage, international mix, and disciplined expansion

Nephrocare Health Services Limited, which operates under the NephroPlus brand, began FY27 with a strong quarter on both growth and profitability. For the quarter ended June 30, 2026 (Q1 FY27), consolidated revenue from operations rose to ₹281.8 crore, up 23.7% year-on-year from ₹227.8 crore. Profitability scaled faster than revenue. Adjusted EBITDA increased 30.7% YoY to ₹65.1 crore, while adjusted PAT grew 41.7% YoY to ₹36.8 crore.

The quarter’s story was built on a familiar set of levers for a dialysis network: higher volumes, improving realizations, and operating leverage. Treatments increased 13.3% YoY to 10.31 lakh and the active patient base (NephroPlus calls them “Guests”) ended the quarter at 38,262, up 13.0% YoY. Alongside that, revenue per treatment moved up 9.2% YoY to ₹2,733, which management attributed primarily to a higher share of international operations.

What stood out was the consistency between the investor presentation and the management commentary on the earnings call. Management framed the company as a “platform” built in India and replicated across markets where dialysis is reimbursed by payors. That idea helps explain why margin expansion is being driven not only by scale in India, but also by the growing weight of higher realization international markets.

The quarter in numbers: volume growth plus improving realizations

NephroPlus delivered growth across its key operating metrics and improved profitability ratios.

Two financial details also helped reported profits. Finance costs in Q1 FY27 were ₹2.2 crore versus ₹6.1 crore in Q1 FY26. Other income was ₹7.5 crore versus ₹6.6 crore a year ago.

On mix, the investor deck disclosed a Q1 FY27 revenue split of 55% from India and 45% from international markets. That matters because realizations per treatment are structurally higher outside India. The company’s own market slide highlighted the difference in pricing per treatment across geographies, ranging from about US$22 in India to much higher levels in markets such as the Philippines, Uzbekistan, and KSA.

Network expansion and the “platform” approach

NephroPlus positioned itself as India’s and Asia’s largest dialysis network and stated that it operates 550 clinics globally across 357 cities in 5 countries. As of June 30, 2026, it had 487 clinics in India across 307 cities and 63 clinics across the Philippines, Uzbekistan and Nepal, with 1 clinic in KSA.

During Q1 FY27, the company added 26 clinics, including 19 clinics in India and 7 clinics in the Philippines. On the call, management also highlighted city additions: 17 new cities in India and 5 new cities in the Philippines.

The Philippines remained central to the international narrative. Management said it crossed 50 clinics in the Philippines and now operates 51 clinics across 39 cities. It described the market as highly fragmented, with around 900 clinics, many owned by small operators. In that context, NephroPlus framed its scale, procurement, and operating protocols as key advantages.

The company’s asset-light positioning is also linked to its clinic formats. As of June 30, 2026, it reported 272 captive clinics (inside private hospitals), 200 PPP clinics (inside government hospitals), and 78 standalone clinics. This mix is important because a large share of expansion can happen without the real estate burden of building hospitals, while still enabling a wide distribution footprint.

Margin expansion and cost control: what management credited

Adjusted EBITDA margin expanded 120 bps YoY to 23.1% in Q1 FY27. It also improved 220 bps sequentially versus Q4 FY26.

On the call, the CFO linked part of the margin improvement to better cost of goods sold efficiency and the ability to carry the India operating model and procurement scale into higher price-point markets. This was consistent with the broader thesis the company has articulated: that India’s low price point forces process discipline, and that discipline can produce attractive unit economics when applied in better reimbursed markets.

The company’s platform narrative was also supported by its focus on internal capability building. NephroPlus launched the NephroPlus International Dialysis Academy (NIDA), an in-house training program based in India and the Philippines. Management said the first batch will begin training in Q3 FY27. The intent is straightforward: international expansion can be constrained by the availability of trained renal nurses, and NIDA is positioned as a structural solution.

In addition, management discussed technology-driven initiatives, including the NephroPlus Index, a composite health score derived from seven weighted clinical metrics. It was stated to be live across 29 centers and 2,600 guests, with plans to aggregate it at clinic, cluster, zone, and country levels over coming quarters.

Saudi Arabia: progress, but still a timing risk

Saudi Arabia remains a strategic market, but it is still in an investment and readiness phase.

In the investor deck, the company stated that home dialysis treatments commenced, it obtained the medical operator license, and it submitted the Ministry of Health tender RFI. On the earnings call, management added that the first clinic at Riyadh Hospital became operational in July and that home dialysis has commenced there as well.

However, management was clear that scaling depends on the government tendering process and that timelines are not fully within the company’s control. Financially, Q1 FY27 results included a share of loss of associate of ₹3.6 crore, and the company added back this Saudi/JV related item (net of tax) to compute adjusted PAT.

For investors, the key takeaway is that Saudi is being built with a tender-led scaling model in mind. It can create meaningful upside if the tender scale is large, but it also introduces execution and timing uncertainty.

Balance sheet and cash flow context from FY26

While Q1 FY27 was the focus, the presentation also provided consolidated financial statements up to FY26. In FY26, the company reported revenue from operations of ₹998.8 crore and EBITDA of ₹227.0 crore, with PAT of ₹76.8 crore.

The FY26 balance sheet showed total assets of ₹1,470.9 crore and trade receivables of ₹316.9 crore. Working capital dynamics were discussed on the call as structurally higher due to government payer cycles, where payments typically come in three to four months.

FY26 consolidated cash flow showed net cash from operating activities of ₹232.6 crore and net cash used in investing activities of ₹410.4 crore.

What to watch from here

NephroPlus reiterated its medium-term revenue growth guidance of 15% to 20% over the next three to five years. It also gave a strategic expansion marker: 40 to 50 clinics in India annually and 10 to 15 clinics in the Philippines annually, alongside an intent to add a new international market every 12 to 18 months.

The near-term investment debate is likely to center on how quickly international scale builds without diluting margins, and how Saudi progresses through its tender cycle. At the same time, the company’s Q1 FY27 performance reinforced a core point management emphasized: revenue is being driven by treatment volumes and improving realizations, while profitability is scaling faster due to operating leverage.

In a business where capacity addition and protocol-driven execution are often the difference between steady compounding and operational noise, NephroPlus is positioning itself as a scaled operator with an exportable operating system. Q1 FY27 suggests the system is working, while leaving enough open questions for investors to track the next set of execution milestones.